AU2002309141B2 - Vaccine for modulating between T1 and T2 immune responses - Google Patents
Vaccine for modulating between T1 and T2 immune responses Download PDFInfo
- Publication number
- AU2002309141B2 AU2002309141B2 AU2002309141A AU2002309141A AU2002309141B2 AU 2002309141 B2 AU2002309141 B2 AU 2002309141B2 AU 2002309141 A AU2002309141 A AU 2002309141A AU 2002309141 A AU2002309141 A AU 2002309141A AU 2002309141 B2 AU2002309141 B2 AU 2002309141B2
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- dilipopeptide
- muc
- lipid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 46
- 230000028993 immune response Effects 0.000 title claims description 50
- 108010028921 Lipopeptides Proteins 0.000 claims abstract description 36
- 230000002163 immunogen Effects 0.000 claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 175
- 239000000203 mixture Substances 0.000 claims description 94
- 150000002632 lipids Chemical class 0.000 claims description 79
- 239000002502 liposome Substances 0.000 claims description 72
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 35
- 230000000890 antigenic effect Effects 0.000 claims description 34
- 201000004792 malaria Diseases 0.000 claims description 33
- 201000008827 tuberculosis Diseases 0.000 claims description 30
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 25
- 239000002671 adjuvant Substances 0.000 claims description 20
- 230000006052 T cell proliferation Effects 0.000 claims description 8
- 230000016784 immunoglobulin production Effects 0.000 claims description 8
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 2
- 239000004576 sand Substances 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 12
- 230000028996 humoral immune response Effects 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 7
- 238000009472 formulation Methods 0.000 description 54
- 230000003053 immunization Effects 0.000 description 35
- 238000002649 immunization Methods 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 29
- 208000002672 hepatitis B Diseases 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 24
- 102000036639 antigens Human genes 0.000 description 24
- 239000000427 antigen Substances 0.000 description 23
- 229940027941 immunoglobulin g Drugs 0.000 description 22
- 102100034256 Mucin-1 Human genes 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 230000008348 humoral response Effects 0.000 description 16
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000036755 cellular response Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000000612 antigen-presenting cell Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 230000005875 antibody response Effects 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 239000002691 unilamellar liposome Substances 0.000 description 5
- 101000801058 Homo sapiens TM2 domain-containing protein 2 Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 108010008707 Mucin-1 Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 102100033691 TM2 domain-containing protein 2 Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- -1 cysteine amino acids Chemical class 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000029226 lipidation Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OLDGKSQBWGEFNM-FQEVSTJZSA-N (2s)-6-amino-2-(hexadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCCCN OLDGKSQBWGEFNM-FQEVSTJZSA-N 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- OLDGKSQBWGEFNM-UHFFFAOYSA-N Nalpha -palmitoyl-lysine Natural products CCCCCCCCCCCCCCCC(=O)NC(C(O)=O)CCCCN OLDGKSQBWGEFNM-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009172 cell transfer therapy Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- DEHHYUARFKIUDI-UHFFFAOYSA-N 3-phenylprop-2-yn-1-amine Chemical compound NCC#CC1=CC=CC=C1 DEHHYUARFKIUDI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 101150026926 JBP1 gene Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000057860 human MUC1 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- KXJTWOGIBOWZDJ-LELJLAJGSA-N l-blp25 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C1=CNC=N1 KXJTWOGIBOWZDJ-LELJLAJGSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 101150097768 prmt5 gene Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 125000004354 sulfur functional group Chemical group 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Optical Communication System (AREA)
- Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27869801P | 2001-03-27 | 2001-03-27 | |
| US60/278,698 | 2001-03-27 | ||
| PCT/IB2002/002188 WO2002076485A2 (en) | 2001-03-27 | 2002-03-27 | Vaccine for modulating between t1 and t2 immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002309141A1 AU2002309141A1 (en) | 2003-03-27 |
| AU2002309141B2 true AU2002309141B2 (en) | 2007-08-09 |
Family
ID=23065998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002309141A Ceased AU2002309141B2 (en) | 2001-03-27 | 2002-03-27 | Vaccine for modulating between T1 and T2 immune responses |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8198400B2 (https=) |
| EP (1) | EP1377275B1 (https=) |
| JP (2) | JP2004533421A (https=) |
| AT (1) | ATE343375T1 (https=) |
| AU (1) | AU2002309141B2 (https=) |
| CA (1) | CA2441809C (https=) |
| DE (1) | DE60215627T2 (https=) |
| ES (1) | ES2424131T3 (https=) |
| WO (1) | WO2002076485A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004533421A (ja) | 2001-03-27 | 2004-11-04 | バイオミラ，インコーポレイテッド | Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン |
| ES2375992T3 (es) * | 2002-04-15 | 2012-03-08 | Oncothyreon Inc. | Glucolipopéptidos sintéticos como vacunas. |
| EP1677773A1 (en) * | 2003-10-14 | 2006-07-12 | Biomira, Inc. | Combination therapy for cancer |
| TWI395591B (zh) * | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| US8871250B2 (en) | 2005-06-28 | 2014-10-28 | Oncothyreon Inc. | Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine |
| WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| US8703180B1 (en) * | 2007-10-23 | 2014-04-22 | Abbott Cardiovascular Systems Inc. | Multiple growth factor compositions, methods of fabrication, and methods of treatment |
| ES2555858T3 (es) * | 2009-03-24 | 2016-01-11 | Transgene Sa | Biomarcador para el control de pacientes |
| CN102483405B (zh) | 2009-07-10 | 2015-12-02 | 特朗斯吉有限公司 | 用于选择患者的生物标志物及相关方法 |
| EP2678005A4 (en) | 2011-02-24 | 2015-06-10 | Oncothyreon Inc | GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS |
| CA2935511C (en) | 2014-01-07 | 2023-04-04 | Babita Agrawal | Immunomodulatory compositions comprising heat-killed caulobacter crescentus and methods of use thereof |
| CN107921113A (zh) | 2015-08-25 | 2018-04-17 | 巴比塔·阿格拉沃尔 | 免疫调节组合物及其使用方法 |
| CN110418648B (zh) * | 2017-02-22 | 2023-09-08 | 丁恩雨 | 一种编码人GM-CSF与多串连表位融合的mRNA癌症疫苗 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580563A (en) * | 1992-05-01 | 1996-12-03 | Tam; James P. | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof |
| WO1997038010A2 (en) * | 1996-04-11 | 1997-10-16 | The University Of British Columbia | Fusogenic liposomes |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5019383A (en) | 1981-01-09 | 1991-05-28 | New York Blood Center, Inc. | Fatty acid carriers for synthetic peptides |
| ZA831547B (en) | 1982-03-15 | 1984-10-31 | New York Blood Center Inc | Fatty acid carriers for synthetic vaccines |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US6090406A (en) * | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5837249A (en) | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
| DE3683688D1 (de) | 1985-04-19 | 1992-03-12 | Wistar Inst | Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. |
| IT1213029B (it) | 1986-01-30 | 1989-12-07 | Bracco Ind Chimica Spa | Chelati di ioni metallici paramagnetici. |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4868155A (en) | 1987-10-05 | 1989-09-19 | Merck & Co., Inc. | Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts |
| US5993823A (en) | 1990-12-18 | 1999-11-30 | Institut Pasteur De Lille | Cytotoxic T lymphocyte-inducing lipopeptides and methods of use |
| FR2670787B1 (fr) | 1990-12-18 | 1995-06-23 | Pasteur Institut | Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins. |
| US5871746A (en) | 1990-12-18 | 1999-02-16 | Institut National De La Sainte Et De La Recherche Medicale (Inserm) | Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines |
| ES2044781B1 (es) | 1992-04-14 | 1994-10-01 | Menarini Lab | Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2 |
| US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| AU2247095A (en) | 1994-04-12 | 1995-10-30 | Biomira Inc. | Cellular immune response-specific antigens and uses therefor |
| WO1995029927A2 (en) | 1994-05-02 | 1995-11-09 | Biomira, Inc. | Process for preparation of glycosides of tumor-associated carbohydrate antigens |
| AU6260796A (en) | 1995-06-07 | 1996-12-30 | National Jewish Center For Immunology And Respiratory Medicine | Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof |
| AUPN568095A0 (en) | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| JP2001510440A (ja) | 1996-03-20 | 2001-07-31 | スローン―ケタリング・インスティテュート・フォー・キャンサー・リサーチ | ムチン接合体ペプチドワクチン |
| US5910306A (en) * | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
| CA2289742C (en) | 1997-05-08 | 2013-07-16 | Biomira Inc. | Method for generating activated t-cells and antigen-pulsed antigen-presenting cells |
| FR2774687B1 (fr) * | 1998-02-06 | 2002-03-22 | Inst Nat Sante Rech Med | Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques |
| FR2776926B1 (fr) * | 1998-04-07 | 2003-10-24 | Inst Nat Sante Rech Med | Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination |
| US20020051813A1 (en) | 1999-01-15 | 2002-05-02 | Lawrence Boni | Lipomatrix preparation |
| ATE290879T1 (de) | 1999-08-18 | 2005-04-15 | Altarex Medical Corp | Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung |
| US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
| CA2383737C (en) | 1999-09-08 | 2011-01-18 | Transgene S.A. | Muc-1 derived peptides |
| ATE518874T1 (de) | 1999-11-15 | 2011-08-15 | Oncothyreon Inc | Synthetische lipid-a analogen und verwendungen davon |
| WO2001070265A2 (en) | 2000-03-24 | 2001-09-27 | Biomira, Inc. | Lipopeptide adjuvants |
| EP1182210A1 (en) | 2000-08-17 | 2002-02-27 | BASTERT, Gunter, Prof.Dr.med.Dr.h.c. | Epitopes of tumor-associated MUC1 antigen |
| AU2002219998B2 (en) | 2000-12-01 | 2006-03-02 | Biomira, Inc. | Preparation of large liposomes by infusion into peg |
| JP2004533421A (ja) | 2001-03-27 | 2004-11-04 | バイオミラ，インコーポレイテッド | Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン |
| ES2375992T3 (es) | 2002-04-15 | 2012-03-08 | Oncothyreon Inc. | Glucolipopéptidos sintéticos como vacunas. |
| JP5014573B2 (ja) | 2002-05-09 | 2012-08-29 | オンコサイレオン インコーポレーテッド | 脂質ａおよび他の炭水化物リガンド類似体 |
| TWI395591B (zh) | 2004-04-01 | 2013-05-11 | Oncothyreon Inc | 黏液性糖蛋白（ｍｕｃ-１）疫苗 |
| US8871250B2 (en) | 2005-06-28 | 2014-10-28 | Oncothyreon Inc. | Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine |
-
2002
- 2002-03-27 JP JP2002574998A patent/JP2004533421A/ja not_active Withdrawn
- 2002-03-27 CA CA2441809A patent/CA2441809C/en not_active Expired - Fee Related
- 2002-03-27 AU AU2002309141A patent/AU2002309141B2/en not_active Ceased
- 2002-03-27 ES ES06022033T patent/ES2424131T3/es not_active Expired - Lifetime
- 2002-03-27 WO PCT/IB2002/002188 patent/WO2002076485A2/en not_active Ceased
- 2002-03-27 DE DE60215627T patent/DE60215627T2/de not_active Expired - Lifetime
- 2002-03-27 EP EP02735795A patent/EP1377275B1/en not_active Expired - Lifetime
- 2002-03-27 AT AT02735795T patent/ATE343375T1/de not_active IP Right Cessation
- 2002-03-27 US US10/106,876 patent/US8198400B2/en not_active Expired - Fee Related
-
2010
- 2010-11-15 JP JP2010255171A patent/JP5519477B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-02 US US13/462,356 patent/US20120269885A1/en not_active Abandoned
- 2012-05-02 US US13/462,314 patent/US8552145B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580563A (en) * | 1992-05-01 | 1996-12-03 | Tam; James P. | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof |
| WO1997038010A2 (en) * | 1996-04-11 | 1997-10-16 | The University Of British Columbia | Fusogenic liposomes |
Non-Patent Citations (1)
| Title |
|---|
| Guan et al. "Liposmal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses." Bioconjugate Chemistry, July 1998, 9(4): 451-458. XP002186768, ISSN:1043-1802 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1377275A2 (en) | 2004-01-07 |
| DE60215627T2 (de) | 2007-07-19 |
| WO2002076485A3 (en) | 2003-05-30 |
| US8552145B2 (en) | 2013-10-08 |
| ATE343375T1 (de) | 2006-11-15 |
| CA2441809A1 (en) | 2002-10-03 |
| ES2424131T3 (es) | 2013-09-27 |
| WO2002076485A2 (en) | 2002-10-03 |
| CA2441809C (en) | 2014-07-22 |
| US20120269885A1 (en) | 2012-10-25 |
| DE60215627D1 (de) | 2006-12-07 |
| JP2011105720A (ja) | 2011-06-02 |
| US8198400B2 (en) | 2012-06-12 |
| JP2004533421A (ja) | 2004-11-04 |
| EP1377275B1 (en) | 2006-10-25 |
| US20030157160A1 (en) | 2003-08-21 |
| JP5519477B2 (ja) | 2014-06-11 |
| US20120269884A1 (en) | 2012-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8552145B2 (en) | Vaccine for modulating between T1 and T2 immune responses | |
| EP1634949B1 (en) | Method for generating activated T-cells and antigen-pulsed antigen-presenting cells | |
| CA2564778A1 (en) | Vaccines | |
| KR100850473B1 (ko) | 면역원성이 불량한 항원의 면역원성을 향상시키는 약제조성물 | |
| AU2002309141A1 (en) | Vaccine for modulating between T1 and T2 immune responses | |
| JP2004523494A6 (ja) | 低免疫原性抗原の免疫原性を増強する医薬組成物 | |
| WO2002034287A2 (en) | Therapeutic vaccine formulations containing chitosan | |
| US20020018806A1 (en) | Lipopeptide adjuvants | |
| US20040037840A1 (en) | Novel therapeutic vaccine formulations | |
| TWI457145B (zh) | 以被包封於微脂粒內之蒂卡琳素（ｓｔｉｃｈｏｌｙｓｉｎ）為基礎的疫苗組成物 | |
| US20100266672A1 (en) | Vaccines | |
| EP1852126B1 (en) | Vaccine for modulating between T1 and T2 immune responses | |
| HK1177138B (en) | Vaccine compositions based on sticholysin encapsulated in liposomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT FROM BIOMIRA, INC. TO BIOMIRA INC. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: ONCOTHYREON INC. Free format text: FORMER OWNER WAS: BIOMIRA INC. |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |